Abstract
Oxytocin (OT) and arginine vasopressin (AVP) are two small, related neuropeptides found in many mammalian species, including humans. These neuropeptides are associated with a range of social behaviors and their dysregulation has been associated with deficits in social behavior. In particular, the OT neuropeptide system has been investigated in Autism Spectrum Disorder (ASD), as well as in Prader-Willi Syndrome (PWS), Williams Syndrome (WS) and Fragile X Syndrome (FXS), all of which are characterized by marked social deficits. PWS, WS and FXS are caused by identified genetic mutations and provide insight into the developmental influences of the OT system. In particular, FXS is caused by a mutation in a single gene and up to 47 % of patients with FXS are diagnosed with ASD or also have autism related behaviors. Animal models of genetic neurodevelopmental disorders (NDD) are becoming a valuable tool to examine the role and relatedness of OT and AVP in the developing brain. We provide an example of how OT and AVP systems are altered with a mutation in the mouse Fragile X mental retardation 1 (Fmr1) gene which leads to FXS-like symptoms in Fmr1 knockout (KO) mice. By studying the OT and AVP systems in these rare disorders, we may further understand their mechanisms of action in ASD and in typical development. This chapter will summarize the current data pertaining to these NDD and the systems of OT and AVP.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abramson RK, Wright HH, Carpenter R, Brennan W, Lumpuy O, Cole E, Young SR (1989) Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord 19:397–407
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington
Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, Hollander E (2012) Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 3:16
Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A (2010) Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A 107:4389–4394
Appenrodt E, Schnabel R, Schwarzberg H (1998) Vasopressin administration modulates anxiety-related behavior in rats. Physiol Behav 64:543–547
Ashley CT Jr, Wilkinson KD, Reines D, Warren ST (1993) FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262:563–566
Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M (1995) Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 25:63–77
Bakker CE, Verheij C, Willemsen R, Vanderhelm R, Oerlemans F, Vermey M, Bygrave A, Hoogeveen AT, Oostra BA, Reyniers E, Deboulle K, Dhooge R, Cras P, Vanvelzen D, Nagels G, Martin JJ, Dedeyn PP, Darby JK, Willems PJ (1994) Fmr1 knockout mice—a model to study fragile-X mental-retardation. Cell 78:23–33
Bartz JA, Hollander E (2006) The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior. Horm Behav 50:518–528
Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E (2008) Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58:639–650
Bernardet M, Crusio WE (2006) Fmr1 KO mice as a possible model of autistic features. Scientific World Journal 6:1164–1176
Berry-Kravis E, Grossman AW, Crnicz LS, Greenough WT (2002) Understanding fragile X syndrome. Curr Paediatr 12:316–324
Berry-Kravis E, Knox A, Hervey C (2011) Targeted treatments for fragile X syndrome. J Neurodev Disord 3:193–210
Betancur C (2011) Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 1380:42–77
Bittel DC, Kibiryeva N, McNulty SG, Driscoll DJ, Butler MG, White RA (2007a) Whole genome microarray analysis of gene expression in an imprinting center deletion mouse model of Prader-Willi syndrome. Am J Med Genet A 143:422–429
Bittel DC, Kibiryeva N, Sell SM, Strong TV, Butler MG (2007b) Whole genome microarray analysis of gene expression in Prader-Willi syndrome. Am J Med Genet A 143:430–442
Boccaccio I, Glatt-Deeley H, Watrin F, Roeckel N, Lalande M, Muscatelli F (1999) The human MAGEL2 gene and its mouse homologue are paternally expressed and mapped to the Prader-Willi region. Hum Mol Genet 8:2497–2505
Bolton PF, Dennis NR, Browne CE, Thomas NS, Veltman MW, Thompson RJ, Jacobs P (2001) The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. Am J Med Genet 105:675–685
Borghgraef M, Fryns JP, Van Den Berghe H (1990) Psychological profile and behavioural characteristics in 12 patients with Prader-Willi syndrome. Genet Counsel 1:141–150
Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5:514–516
Brown WT (1990) The fragile X: progress toward solving the puzzle. Am J Hum Genet 47:175–180
Campbell DB, Datta D, Jones ST, Batey Lee E, Sutcliffe JS, Hammock EA, Levitt P (2011) Association of oxytocin receptor (OXTR) gene variants with multiple phenotype domains of autism spectrum disorder. J Neurodev Disord 3:101–112
Carter CS (1998) Neuroendocrine perspectives on social attachment and love. Psychoneuroendocrinology 23:779–818
Carter CS (2007) Sex differences in oxytocin and vasopressin: implications for autism spectrum disorders? Behav Brain Res 176:170–186
Cascio CJ, Foss-Feig JH, Heacock JL, Newsom CR, Cowan RL, Benningfield MM, Rogers BP, Cao A (2012) Response of neural reward regions to food cues in autism spectrum disorders. J Neurodev Disord 4:9
Cassidy SB, Schwartz S, Miller JL, Driscoll DJ (2012) Prader-Willi syndrome. Genet Med 14:10–26
Ceman S, Nelson R, Warren ST (2000) Identification of mouse YB1/p50 as a component of the FMRP-associated mRNP particle. Biochem Biophys Res Comm 279:904–908
Chaste P, Leboyer M (2012) Autism risk factors: genes, environment, and gene-environment interactions. Dialogue Clin Neurosci 14:281–292
Chen L, Toth M (2001) Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neurosci 103:1043–1050
Chini B, Mouillac B, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Andriolo M, Pupier S, Jard S, Barberis C (1996) Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett 397:201–206
Cho MM, DeVries AC, Williams JR, Carter CS (1999) The effects of oxytocin and vasopressin on partner preferences in male and female prairie voles (Microtus ochrogaster). Behav Neurosci 113:1071–1079
Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT (1999) Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 45:287–295
Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, Greenough WT (1997) Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A 94:5401–5404
Cook EH Jr, Lindgren V, Leventhal BL, Courchesne R, Lincoln A, Shulman C, Lord C, Courchesne E (1997) Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am J Hum Genet 60:928–934
Corbin F, Bouillon M, Fortin A, Morin S, Rousseau F, Khandjian EW (1997) The fragile X mental retardation protein is associated with poly(A)+mRNA in actively translating polyribosomes. Hum Mol Genet 6:1465–1472
Cornish KM, Munir F, Cross G (1999) Spatial cognition in males with Fragile-X syndrome: evidence for a neuropsychological phenotype. Cortex 35:263–271
Crawley JN, Chen T, Puri A, Washburn R, Sullivan TL, Hill JM, Young NB, Nadler JJ, Moy SS, Young LJ, Caldwell HK, Young WS (2007) Social approach behaviors in oxytocin knockout mice: comparison of two independent lines tested in different laboratory environments. Neuropeptides 41:145–163
Cronbach LJ, Meehl PE (1955) Construct validity in psychological tests. Psychol Bull 52:281–302
D’Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K, Kooy RF, Oostra BA, Willems PJ, De Deyn PP (1997) Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 76:367–376
Dadds MR, Macdonald E, Cauchi A, Williams K, Levy F, Brennan J (2014) Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord 44:521–531
Dai L, Carter CS, Ying J, Bellugi U, Pournajafi-Nazarloo H, Korenberg JR (2012) Oxytocin and vasopressin are dysregulated in Williams Syndrome, a genetic disorder affecting social behavior. PloS One 7:e38513
Davidovic L, Navratil V, Bonaccorso CM, Catania MV, Bardoni B, Dumas ME (2011) A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model. Genome Res 21:2190–2202
De Boulle K, Verkerk AJ, Reyniers E, Vits L, Hendrickx J, Van Roy B, Van den Bos F, de Graaff E, Oostra BA, Willems PJ (1993) A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 3:31–35
Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL (1993) The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet 4:335–340
Dimitropoulos A, Feurer ID, Roof E, Stone W, Butler MG, Sutcliffe J, Thompson T (2000) Appetitive behavior, compulsivity, and neurochemistry in Prader-Willi syndrome. Ment Retard Dev Disabil Res Rev 6:125–130
Dimitropoulos A, Ho AY, Klaiman C, Koenig K, Schultz RT (2009) A comparison of behavioral and emotional characteristics in children with autism, Prader-Willi syndrome, and Williams syndrome. J Ment Health Res Intellect Disabil 2:220–243
Dimitropoulos A, Ho A, Feldman B (2013) Social responsiveness and competence in Prader-Willi syndrome: direct comparison to autism spectrum disorder. J Autism Dev Disord 43:103–113
Dombret C, Nguyen T, Schakman O, Michaud JL, Hardin-Pouzet H, Bertrand MJ, De Backer O (2012) Loss of Maged1 results in obesity, deficits of social interactions, impaired sexual behavior and severe alteration of mature oxytocin production in the hypothalamus. Hum Mol Genet 21:4703–4717
Domes G, Heinrichs M, Michel A, Berger C, Herpertz S (2007) Oxytocin improves “mind-reading” in humans. Biol Psychiatry 61:731–733
Domes G, Sibold M, Schulze L, Lischke A, Herpertz SC, Heinrichs M (2013) Intranasal oxytocin increases covert attention to positive social cues. Psychol Med 43:1747–1753
Eberhart DE, Malter HE, Feng Y, Warren ST (1996) The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet 5:1083–1091
Ebstein RP, Israel S, Lerer E, Uzefovsky F, Shalev I, Gritsenko I, Riebold M, Salomon S, Yirmiya N (2009) Arginine vasopressin and oxytocin modulate human social behavior. Ann N Y Acad Sci 1167:87–102
Ebstein RP, Knafo A, Mankuta D, Chew SH, Lai PS (2012) The contributions of oxytocin and vasopressin pathway genes to human behavior. Horm Behav 61:359–379
Einfeld SL, Tonge BJ, Florio T (1997) Behavioral and emotional disturbance in individuals with Williams syndrome. Am J Ment Retard 102:45–53
Ewart AK, Morris CA, Atkinson D, Jin W, Sternes K, Spallone P, Stock AD, Leppert M, Keating MT (1993) Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet 5:11–16
Feldman R, Zagoory-Sharon O, Weisman O, Schneiderman I, Gordon I, Maoz R, Shalev I, Ebstein RP (2012) Sensitive parenting is associated with plasma oxytocin and polymorphisms in the OXTR and CD38 genes. Biol Psychiatry 72:175–181
Feng Y, Zhang F, Lokey LK, Chastain JL, Lakkis L, Eberhart D, Warren ST (1995) Translational suppression by trinucleotide repeat expansion at FMR1. Science 268:731–734
Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST (1997) FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol Cell 1:109–118
Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT (2000) Social amnesia in mice lacking the oxytocin gene. Nat Genet 25:284–288
Flores CG, Valcante G, Guter S, Zaytoun A, Wray E, Bell L, Jacob S, Lewis MH, Driscoll DJ, Cook EH Jr, Kim SJ (2011) Repetitive behavior profiles: consistency across autism spectrum disorder cohorts and divergence from Prader-Willi syndrome. J Neurodev Disord 3:316–324
Francis SM, Sagar A, Levin-Decanini T, Liu W, Carter CS, Jacob S. (2014) Brain Res. 11;1580:199–218
Frankland PW, Wang Y, Rosner B, Shimizu T, Balleine BW, Dykens EM, Ornitz EM, Silva AJ (2004) Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol Psychiatry 9:417–425
Freund LS, Reiss AL (1991) Cognitive profiles associated with the fra(X) syndrome in males and females. Am J Med Genet 38:542–547
Gagliardi C, Frigerio E, Burt DM, Cazzaniga I, Perrett DI, Borgatti R (2003) Facial expression recognition in Williams syndrome. Neuropsychologia 41:733–738
Gatto CL, Broadie K (2009) Temporal requirements of the fragile X mental retardation protein in modulating circadian clock circuit synaptic architecture. Front Neural Circuits 3:8
Gedeon AK, Baker E, Robinson H, Partington MW, Gross B, Manca A, Korn B, Poustka A, Yu S, Sutherland GR, Mulley JC (1992) Fragile X syndrome without CCG amplification has an FMR1 deletion. Nat Genet 1:341–344
Goodrich-Hunsaker NJ, Wong LM, McLennan Y, Srivastava S, Tassone F, Harvey D, Rivera SM, Simon TJ (2011a) Young adult female fragile X premutation carriers show age- and genetically-modulated cognitive impairments. Brain Cogn 75:255–260
Goodrich-Hunsaker NJ, Wong LM, McLennan Y, Tassone F, Harvey D, Rivera SM, Simon TJ (2011b) Adult female fragile X premutation carriers exhibit age- and CGG repeat length-related impairments on an attentionally based enumeration task. Front Hum Neurosci 5:63
Gosch A, Pankau R (1994) Social-emotional and behavioral adjustment in children with Williams-Beuren syndrome. Am J Med Genet 53:335–339
Gosch A, Pankau R (1997) Personality characteristics and behaviour problems in individuals of different ages with Williams syndrome. Dev Med Child Neurol 39:527–533
Greaves N, Prince E, Evans DW, Charman T (2006) Repetitive and ritualistic behaviour in children with Prader-Willi syndrome and children with autism. J Intellect Disabil Res 50:92–100
Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M (2001) Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 50:609–613
Gross-Tsur V, Landau YE, Benarroch F, Wertman-Elad R, Shalev RS (2001) Cognition, attention, and behavior in Prader-Willi syndrome. J Child Neurol 16:288–290
Guastella AJ, Mitchell PB, Dadds MR (2008) Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 63:3–5
Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB (2010) Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 67:692–694
Gurkan CK, Hagerman RJ (2012) Targeted treatments in autism and fragile X syndrome. Res Autism Spectr Disord 6:1311–1320
Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M (2009) Advances in the treatment of fragile X syndrome. Pediatrics 123:378–390
Hagerman R, Hoem G, Hagerman P (2010) Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol Autism 1:12
Hall SS (2009) Treatments for fragile X syndrome: a closer look at the data. Dev Disabil Res Rev 15:353–360
Hall SS, Lightbody AA, Huffman LC, Lazzeroni LC, Reiss AL (2009) Physiological correlates of social avoidance behavior in children and adolescents with fragile x syndrome. J Am Acad Child Adolesc Psychiatry 48:320–329
Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL (2012) Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology 37:509–518
Hammock E, Veenstra-VanderWeele J, Yan Z, Kerr TM, Morris M, Anderson GM, Carter CS, Cook EH, Jacob S (2012) Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems. J Am Acad Child Adolesc Psychiatry 51:712–721
Hampson DR, Adusei DC, Pacey LK (2011) The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. Biochem Pharmacol 81:1078–1086
Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey DB Jr, Roberts J, Mirrett P (2006) Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 140A:1804–1813
Heinrichs M, Domes G (2008) Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog Brain Res 170:337–350
Hessl D, Dyer-Friedman J, Glaser B, Wisbeck J, Barajas RG, Taylor A, Reiss AL (2001) The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics 108:E88
Hinton VJ, Brown WT, Wisniewski K, Rudelli RD (1991) Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet 41:289–294
Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S (2003) Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology 28:193–198
Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S (2007) Oxytocin increases retention of social cognition in autism. Biol Psychiatry 61:498–503
Huber KM, Gallagher SM, Warren ST, Bear MF (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 99:7746–7750
Irwin SA, Galvez R, Greenough WT (2000) Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10:1038–1044
Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP, Kooy F, Willems PJ, Cras P, Kozlowski PB, Swain RA, Weiler IJ, Greenough WT (2001) Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet 98:161–167
Irwin SA, Idupulapati M, Gilbert ME, Harris JB, Chakravarti AB, Rogers EJ, Crisostomo RA, Larsen BP, Mehta A, Alcantara CJ, Patel B, Swain RA, Weiler IJ, Oostra BA, Greenough WT (2002) Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am J Med Genet 111:140–146
Irwin SA, Christmon CA, Grossman AW, Galvez R, Kim SH, DeGrush BJ, Weiler IJ, Greenough WT (2005) Fragile X mental retardation protein levels increase following complex environment exposure in rat brain regions undergoing active synaptogenesis. Neurobiol Learn Mem 83:180–187
Ishak WW, Kahloon M, Fakhry H (2011) Oxytocin role in enhancing well-being: a literature review. J Affect Disord 130:1–9
Jacob S, Brune CW, Carter CS, Leventhal BL, Lord C, Cook EH Jr (2007) Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neurosci Lett 417:6–9
Jansen LM, Gispen-de Wied CC, Wiegant VM, Westenberg HG, Lahuis BE, van Engeland H (2006) Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder. J Autism Dev Disord 36:891–899
Jarvinen-Pasley A, Bellugi U, Reilly J, Mills DL, Galaburda A, Reiss AL, Korenberg JR (2008) Defining the social phenotype in Williams syndrome: a model for linking gene, the brain, and behavior. Dev Psychopathol 20:1–35
Jarvinen-Pasley A, Adolphs R, Yam A, Hill KJ, Grichanik M, Reilly J, Mills D, Reiss AL, Korenberg JR, Bellugi U (2010) Affiliative behavior in Williams syndrome: social perception and real-life social behavior. Neuropsychologia 48:2110–2119
Jarvinen A, Korenberg JR, Bellugi U (2013) The social phenotype of Williams syndrome. Curr Opin Neurobiol 23:414–422
Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL (1992) Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322–327
Jin D, Liu HX, Hirai H, Torashima T, Nagai T, Lopatina O, Shnayder NA, Yamada K, Noda M, Seike T, Fujita K, Takasawa S, Yokoyama S, Koizumi K, Shiraishi Y, Tanaka S, Hashii M, Yoshihara T, Higashida K, Islam MS, Yamada N, Hayashi K, Noguchi N, Kato I, Okamoto H, Matsushima A, Salmina A, Munesue T, Shimizu N, Mochida S, Asano M, Higashida H (2007) CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446:41–45
Kanner L (1943) Autistic disturbances of affective contact. Nerv Child 2:217–250
Kenkel WM, Paredes J, Yee JR, Pournajafi-Nazarloo H, Bales KL, Carter CS (2012) Neuroendocrine and behavioural responses to exposure to an infant in male prairie voles. J Neuroendocrinol 24:874–886
Khandjian EW, Corbin F, Woerly S, Rousseau F (1996) The fragile X mental retardation protein is associated with ribosomes. Nat Genet 12:91–93
Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A (2005) Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25:11489–11493
Korenberg JR, Chen XN, Hirota H, Lai Z, Bellugi U, Burian D, Roe B, Matsuoka R (2000) VI. Genome structure and cognitive map of Williams syndrome. J Cogn Neurosci 12(Suppl 1):89–107
Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin increases trust in humans. Nature 435:673–676
Kuperman S, Beeghly JH, Burns TL, Tsai LY (1985) Serotonin relationships of autistic probands and their first-degree relatives. J Am Acad Child Psychiatry 24:186–190
Kwon H, Menon V, Eliez S, Warsofsky IS, White CD, Dyer-Friedman J, Taylor AK, Glover GH, Reiss AL (2001) Functional neuroanatomy of visuospatial working memory in fragile X syndrome: relation to behavioral and molecular measures. Am J Psychiatry 158:1040–1051
Landgraf R, Wigger A (2003) Born to be anxious: neuroendocrine and genetic correlates of trait anxiety in HAB rats. Stress 6:111–119
Larson J, Jessen RE, Kim D, Fine AK, du Hoffmann J (2005) Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. J Neurosci 25:9460–9469
Lavi-Itzkovitz A, Tcherpakov M, Levy Z, Itzkovitz S, Muscatelli F, Fainzilber M (2012) Functional consequences of necdin nucleocytoplasmic localization. PLoS One 7:e33786
Leboyer M, Philippe A, Bouvard M, Guilloud-Bataille M, Bondoux D, Tabuteau F, Feingold J, Mouren-Simeoni MC, Launay JM (1999) Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psychiatry 45:158–163
Lerer E, Levi S, Israel S, Yaari M, Nemanov L, Mankuta D, Nurit Y, Ebstein RP (2010) Low CD38 expression in lymphoblastoid cells and haplotypes are both associated with autism in a family-based study. Autism Res 3:293–302
Leventhal BL, Cook EH Jr, Morford M, Ravitz A, Freedman DX (1990) Relationships of whole blood serotonin and plasma norepinephrine within families. J Autism Dev Disord 20:499–511
Li J, Pelletier MR, Perez Velazquez JL, Carlen PL (2002) Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 19:138–151
Lim MM, Wang Z, Olazabal DE, Ren X, Terwilliger EF, Young LJ (2004) Enhanced partner preference in a promiscuous species by manipulating the expression of a single gene. Nature 429:754–757
Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659–685
Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M (2000) The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30:205–223
Lowery MC, Morris CA, Ewart A, Brothman LJ, Zhu XL, Leonard CO, Carey JC, Keating M, Brothman AR (1995) Strong correlation of elastin deletions, detected by FISH, with Williams syndrome: evaluation of 235 patients. Am J Hum Genet 57:49–53
Macdonald K, Feifel D (2013) Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci 7:35
Macdonald K, Macdonald TM (2010) The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 18:1–21
Maes B, Fryns JP, Van Walleghem M, Van den Berghe H (1994) Cognitive functioning and information processing of adult mentally retarded men with fragile-X syndrome. Am J Med Genet 50:190–200
Martin A, State M, Anderson GM, Kaye WM, Hanchett JM, McConaha CW, North WG, Leckman JF (1998) Cerebrospinal fluid levels of oxytocin in Prader-Willi syndrome: a preliminary report. Biol Psychiatry 44:1349–1352
McCullough, ME, Churchland, PS, Mendez, AJ (2013). Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neurosci Biobehav Rev 37:1485–1492
McLennan Y, Polussa J, Tassone F, Hagerman R (2011) Fragile X syndrome. Curr Genomics 12:216–224
Mervis CB, Morris CA, Klein-Tasman BP, Bertrand J, Kwitny S, Appelbaum LG, Rice CE (2003) Attentional characteristics of infants and toddlers with Williams syndrome during triadic interactions. Dev Neuropsychol 23:243–268
Miller M, Bales KL, Taylor SL, Yoon J, Hostetler CM, Carter CS, Solomon M (2013) Oxytocin and vasopressin in children and adolescents with autism spectrum disorders: sex differences and associations with symptoms. Autism Res 6:91–102
Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE (2002) Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12:39–46
Mineur YS, Huynh LX, Crusio WE (2006) Social behavior deficits in the Fmr1 mutant mouse. Behavioural Brain Research 168:172–175
Modahl C, Green L, Fein D, Morris M, Waterhouse L, Feinstein C, Levin H (1998) Plasma oxytocin levels in autistic children. Biol Psychiatry 43:270–277
Morris CA (1993) Williams syndrome. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K (eds) Gene reviews. University of Washington-Seattle, Seattle
Morton JE, Bundey S, Webb TP, MacDonald F, Rindl PM, Bullock S (1997) Fragile X syndrome is less common than previously estimated. J Med Genet 34:1–5
Moy SS, Nadler JJ, Young NB, Nonneman RJ, Grossman AW, Murphy DL, D’Ercole AJ, Crawley JN, Magnuson TR, Lauder JM (2009) Social approach in genetically engineered mouse lines relevant to autism. Genes Brain Behav 8:129–142
Munesue T, Yokoyama S, Nakamura K, Anitha A, Yamada K, Hayashi K, Asaka T, Liu HX, Jin D, Koizumi K, Islam MS, Huang JJ, Ma WJ, Kim UH, Kim SJ, Park K, Kim D, Kikuchi M, Ono Y, Nakatani H, Suda S, Miyachi T, Hirai H, Salmina A, Pichugina YA, Soumarokov AA, Takei N, Mori N, Tsujii M, Sugiyama T, Yagi K, Yamagishi M, Sasaki T, Yamasue H, Kato N, Hashimoto R, Taniike M, Hayashi Y, Hamada J, Suzuki S, Ooi A, Noda M, Kamiyama Y, Kido MA, Lopatina O, Hashii M, Amina S, Malavasi F, Huang EJ, Zhang J, Shimizu N, Yoshikawa T, Matsushima A, Minabe Y, Higashida H (2010) Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci Res 67:181–191
Muscatelli F, Abrous DN, Massacrier A, Boccaccio I, Le Moal M, Cau P, Cremer H (2000) Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum Mol Genet 9:3101–3110
Neumann ID, Landgraf R (2012) Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 35:649–659
Nielsen DM, Derber WJ, McClellan DA, Crnic LS (2002) Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res 927:8–17
O’Donnell WT, Warren ST (2002) A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 25:315–338
Owley T, Brune CW, Salt J, Walton L, Guter S, Ayuyao N, Gibbons RD, Leventhal BL, Cook EH (2010) A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res 3:1–7
Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST (1999) Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94:185–192
Paxinos G, Franklin KBJ (2004) The mouse brain in stereotaxic coordinates, compact 2nd edn. Elsevier Academic Press, Amsterdam
Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL (2000) (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 9:1145–1159
Petrovic P, Kalisch R, Singer T, Dolan RJ (2008) Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci 28:6607–6615
Pietropaolo S, Guilleminot A, Martin B, D’Amato FR, Crusio WE (2011) Genetic-Background Modulation of Core and Variable Autistic-Like Symptoms in Fmr1 Knock-Out Mice. PloS One 6:e17073
Plesa-Skwerer D, Faja S, Schofield C, Verbalis A, Tager-Flusberg H (2006) Perceiving facial and vocal expressions of emotion in individuals with Williams syndrome. Am J Ment Retard 111:15–26
Pretorius PH, King MA, Pan TS, de Vries DJ, Glick SJ, Byrne CL (1998) Reducing the influence of the partial volume effect on SPECT activity quantitation with 3D modelling of spatial resolution in iterative reconstruction. Phys Med Biol 43:407–420
Proulx E, Young EJ, Osborne LR, Lambe EK (2010) Enhanced prefrontal serotonin 5-HT(1A) currents in a mouse model of Williams-Beuren syndrome with low innate anxiety. J Neurodev Disord 2:99–108
Reiss AL, Abrams MT, Greenlaw R, Freund L, Denckla MB (1995) Neurodevelopmental effects of the FMR-1 full mutation in humans. Nat Med 1:159–167
Riby D, Hancock PJ (2009) Looking at movies and cartoons: eye-tracking evidence from Williams syndrome and autism. J Intellect Disabil Res 53:169–181
Rimmele U, Hediger K, Heinrichs M, Klaver P (2009) Oxytocin makes a face in memory familiar. J Neurosci 29:38–42
Rodgers J, Riby DM, Janes E, Connolly B, McConachie H (2012) Anxiety and repetitive behaviours in autism spectrum disorders and Williams syndrome: a cross-syndrome comparison. J Autism Dev Disord 42:175–180
Rudelli RD, Brown WT, Wisniewski K, Jenkins EC, Laure-Kamionowska M, Connell F, Wisniewski HM (1985) Adult fragile X syndrome. Clinico-neuropathologic findings. Acta neuropathologica 67:289–295
Saitoh S, Buiting K, Cassidy SB, Conroy JM, Driscoll DJ, Gabriel JM, Gillessen-Kaesbach G, Glenn CC, Greenswag LR, Horsthemke B, Kondo I, Kuwajima K, Niikawa N, Rogan PK, Schwartz S, Seip J, Williams CA, Nicholls RD (1997) Clinical spectrum and molecular diagnosis of Angelman and Prader-Willi syndrome patients with an imprinting mutation. Am J Med Genet 68:195–206
Sakurai T, Dorr NP, Takahashi N, McInnes LA, Elder GA, Buxbaum JD (2011) Haploinsufficiency of Gtf2i, a gene deleted in Williams Syndrome, leads to increases in social interactions. Autism Res 4:28–39
Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, Finardi A, Donzelli A, Pattini L, Rubino T, Parolaro D, Nishimori K, Parenti M, Chini B (2011) Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 69:875–882
Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, Chu SH, Moreau MP, Gupta AR, Thomson SA, Mason CE, Bilguvar K, Celestino-Soper PB, Choi M, Crawford EL, Davis L, Wright NR, Dhodapkar RM, DiCola M, DiLullo NM, Fernandez TV, Fielding-Singh V, Fishman DO, Frahm S, Garagaloyan R, Goh GS, Kammela S, Klei L, Lowe JK, Lund SC, McGrew AD, Meyer KA, Moffat WJ, Murdoch JD, O’Roak BJ, Ober GT, Pottenger RS, Raubeson MJ, Song Y, Wang Q, Yaspan BL, Yu TW, Yurkiewicz IR, Beaudet AL, Cantor RM, Curland M, Grice DE, Gunel M, Lifton RP, Mane SM, Martin DM, Shaw CA, Sheldon M, Tischfield JA, Walsh CA, Morrow EM, Ledbetter DH, Fombonne E, Lord C, Martin CL, Brooks AI, Sutcliffe JS, Cook EH Jr, Geschwind D, Roeder K, Devlin B, State MW (2011) Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70:863–885
Sauer C, Montag C, Worner C, Kirsch P, Reuter M (2012) Effects of a common variant in the CD38 gene on social processing in an oxytocin challenge study: possible links to autism. Neuropsychopharmacology 37:1474–1482
Sawchenko PE, Swanson LW (1985) Localization, colocalization, and plasticity of corticotropin-releasing factor immunoreactivity in rat brain. Fed Proc 44:221–227
Schain RJ, Freedman DX (1961) Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 58:315–320
Schapiro MB, Murphy DG, Hagerman RJ, Azari NP, Alexander GE, Miezejeski CM, Hinton VJ, Horwitz B, Haxby JV, Kumar A, White B, Grady CL (1995) Adult fragile X syndrome: neuropsychology, brain anatomy, and metabolism. Am J Med Genet 60:480–493
Schneiderman I, Zagoory-Sharon O, Leckman JF, Feldman R (2012) Oxytocin during the initial stages of romantic attachment: relations to couples’ interactive reciprocity. Psychoneuroendocrinology 37:1277–1285
Schradin C, Kenkel W, Krackow S, Carter CS (2013) Staying put or leaving home: endocrine, neuroendocrine and behavioral consequences in male African striped mice. Horm Behav 63:136–143
Schubert C (2009) The genomic basis of the Williams-Beuren syndrome. Cell Mol Life Sci 66:1178–1197
Seltzer LJ, Ziegler TE, Pollak SD (2010) Social vocalizations can release oxytocin in humans. Proc Biol Sci 277:2661–2666
Shamay-Tsoory SG, Fischer M, Dvash J, Harari H, Perach-Bloom N, Levkovitz Y (2009) Intranasal administration of oxytocin increases envy and schadenfreude (gloating). Biol Psychiatry 66:864–870
Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, Ring RH, Crawley JN (2012) Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Trans Med 4:131ra151
Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G (1993) The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74:291–298
Siomi H, Choi M, Siomi MC, Nussbaum RL, Dreyfuss G (1994) Essential role for KH domains in RNA binding: impaired RNA binding by a mutation in the KH domain of FMR1 that causes fragile X syndrome. Cell 77:33–39
Smith R (2004) Moving molecules: mRNA trafficking in Mammalian oligodendrocytes and neurons. Neuroscientist 10:495–500
Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R (2005) Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 4:420–430
Swaab DF, Purba JS, Hofman MA (1995) Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 80:573–579
Szeto, A, McCabe, PM, Nationmm DA, Tabak, BA, Rossetti, MA, McCullough, ME, Schneiderman, N, Mendez, AJ. (2011) Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin. Psychosom Med 73:393–400
Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, Yanagisawa T, Kimura T, Matzuk MM, Young LJ, Nishimori K (2005) Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci U S A 102:16096–16101
Tassone F, Hagerman RJ, Chamberlain WD, Hagerman PJ (2000a) Transcription of the FMR1 gene in individuals with fragile X syndrome. Am J Med Genet 97:195–203
Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ (2000b) Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 66:6–15
Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, Roge B, Laurier V, Ehlinger V, Arnaud C, Molinas C, Thuilleaux D (2011) Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis 6:47
The Dutch-Belgian Fragile-X Consortium (1994) Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell 78:23–33
Tiedge H, Zhou A, Thorn NA, Brosius J (1993) Transport of BC1 RNA in hypothalamo-neurohypophyseal axons. J Neurosci 13:4214–4219
Todd PK, Mack KJ (2000) Sensory stimulation increases cortical expression of the fragile X mental retardation protein in vivo. Brain Res Mol Brain Res 80:17–25
Todd PK, Mack KJ, Malter JS (2003a) The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95. Proc Natl Acad Sci U S A 100:14374–14378
Todd PK, Malter JS, Mack KJ (2003b) Whisker stimulation-dependent translation of FMRP in the barrel cortex requires activation of type I metabotropic glutamate receptors. Brain Res Mol Brain Res 110:267–278
Tsai TF, Jiang YH, Bressler J, Armstrong D, Beaudet AL (1999) Paternal deletion from Snrpn to Ube3a in the mouse causes hypotonia, growth retardation and partial lethality and provides evidence for a gene contributing to Prader-Willi syndrome. Hum Mol Genet 8:1357–1364
Turner G, Webb T, Wake S, Robinson H (1996) Prevalence of fragile X syndrome. Am J Med Genet 64:196–197
Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen R, Verkerk AJ, Galjaard H, Reuser AJ, Hoogeveen AT, Oostra BA (1993) Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 363:722–724
Vorstman JA, Staal WG, van Daalen E, van Engeland H, Hochstenbach PF, Franke L (2006) Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism. Mol Psychiatry 11:1, 18–28
Wang LW, Berry-Kravis E, Hagerman RJ (2010) Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 7:264–274
Waterhouse L, Fein D, Modahl C (1996) Neurofunctional mechanisms in autism. Psychol Rev 103:457–489
Webb S (2010) Drugmakers dance with autism. Nat Biotechnol 28:772–774
Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, Comery TA, Patel B, Eberwine J, Greenough WT (1997) Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A 94:5395–5400
Weiler IJ, Spangler CC, Klintsova AY, Grossman AW, Kim SH, Bertaina-Anglade V, Khaliq H, de Vries FE, Lambers FA, Hatia F, Base CK, Greenough WT (2004) Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci U S A 101:17504–17509
Whitman BY, Accardo P (1987) Emotional symptoms in Prader-Willi syndrome adolescents. Am J Med Genet 28:897–905
Whittington J, Holland T (2011) Recognition of emotion in facial expression by people with Prader-Willi syndrome. J Intellect Disabil Res 55:75–84
Williams JC, Barratt-Boyes BG, Lowe JB (1961) Supravalvular aortic stenosis. Circulation 24:1311–1318
Wilson BM, Cox CL (2007) Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc Natl Acad Sci U S A 104:2454–2459
Winslow JT, Insel TR (2004) Neuroendocrine basis of social recognition. Curr Opin Neurobiol 14:248–253
Wismer Fries AB, Ziegler TE, Kurian JR, Jacoris S, Pollak SD (2005) Early experience in humans is associated with changes in neuropeptides critical for regulating social behavior. Proc Natl Acad Sci U S A 102:17237–17240
Wisniewski KE, Segan SM, Miezejeski CM, Sersen EA, Rudelli RD (1991) The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. Am J Med Genet 38:476–480
Witt DM, Insel TR (1992) Central oxytocin antagonism decreases female reproductive behavior. Ann N Y Acad Sci 652:445–447
Witt DM, Winslow JT, Insel TR (1992) Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol Biochem Behav 43:855–861
Wohrle D, Kotzot D, Hirst MC, Manca A, Korn B, Schmidt A, Barbi G, Rott HD, Poustka A, Davies KE et al (1992) A microdeletion of less than 250 kb, including the proximal part of the FMR-I gene and the fragile-X site, in a male with the clinical phenotype of fragile-X syndrome. Am J Hum Genet 51:299–306
Wu S, Jia M, Ruan Y, Liu J, Guo Y, Shuang M, Gong X, Zhang Y, Yang X, Zhang D (2005) Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry 58:74–77
Yamamoto Y, Cushing BS, Kramer KM, Epperson PD, Hoffman GE, Carter CS (2004) Neonatal manipulations of oxytocin alter expression of oxytocin and vasopressin immunoreactive cells in the paraventricular nucleus of the hypothalamus in a gender-specific manner. Neuroscience 125:947–955
Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, Bauchwitz RP (2004) A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav 3:337–359
Yrigollen CM, Han SS, Kochetkova A, Babitz T, Chang JT, Volkmar FR, Leckman JF, Grigorenko EL (2008) Genes controlling affiliative behavior as candidate genes for autism. Biol Psychiatry 63:911–916
Zhao MG, Toyoda H, Ko SW, Ding HK, Wu LJ, Zhuo M (2005) Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J Neurosci 25:7385–7392
Acknowledgements
This work was supported in part by NIH K23MH082121 (SJ). The authors would also like to thank Jeanine Leary and Jennifer Speak for their assistance in preparing the text.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Levin-Decanini, T., Francis, S., Sagar, A., Liu, W., Carter, C., Jacob, S. (2015). Oxytocin and Vasopressin in Autism and Genetic Syndromes. In: Fatemi, S. (eds) The Molecular Basis of Autism. Contemporary Clinical Neuroscience. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2190-4_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2190-4_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2189-8
Online ISBN: 978-1-4939-2190-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)